5.05 USD
-0.07 (-1.37%)
We assign a fundamental rating of 4 out of 10 to CVAC. CVAC was compared to 531 industry peers in the Biotechnology industry. Both the profitability and the financial health of CVAC get a neutral evaluation. Nothing too spectacular is happening here. CVAC has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
CVAC had positive earnings in the past year.
CVAC had a negative operating cash flow in the past year.
CVAC had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CVAC reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of CVAC (11.31%) is better than 93.79% of its industry peers.
The Return On Equity of CVAC (14.79%) is better than 94.54% of its industry peers.
CVAC has a better Return On Invested Capital (14.12%) than 95.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROIC | 14.12% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CVAC has a better Profit Margin (182.11%) than 98.68% of its industry peers.
With an excellent Operating Margin value of 212.01%, CVAC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
With an excellent Gross Margin value of 93.01%, CVAC belongs to the best of the industry, outperforming 93.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CVAC is creating value.
CVAC has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CVAC has more shares outstanding
Compared to 1 year ago, CVAC has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.41 indicates that CVAC is not in any danger for bankruptcy at the moment.
CVAC's Altman-Z score of 4.41 is fine compared to the rest of the industry. CVAC outperforms 71.00% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that CVAC is not too dependend on debt financing.
CVAC has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: CVAC outperforms 41.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.41 |
ROIC/WACC1.97
WACC7.18%
2.3 Liquidity
CVAC has a Current Ratio of 3.70. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
CVAC's Current ratio of 3.70 is in line compared to the rest of the industry. CVAC outperforms 43.88% of its industry peers.
CVAC has a Quick Ratio of 3.69. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.69, CVAC is in line with its industry, outperforming 45.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 |
3. Growth
3.1 Past
CVAC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.83%, which is quite impressive.
Looking at the last year, CVAC shows a very negative growth in Revenue. The Revenue has decreased by -86.98% in the last year.
CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
3.2 Future
CVAC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.50% yearly.
CVAC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.88% yearly.
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.43 indicates a rather cheap valuation of CVAC.
Based on the Price/Earnings ratio, CVAC is valued cheaper than 98.49% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.54, CVAC is valued rather cheaply.
CVAC is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.43 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CVAC is valued cheaper than 99.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.56 |
4.3 Compensation for Growth
A cheap valuation may be justified as CVAC's earnings are expected to decrease with -28.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CVAC (12/12/2025, 8:23:19 PM)
5.05
-0.07 (-1.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.45%
Inst Owner Change48.36%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.14B
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts73.33
Price Target4.78 (-5.35%)
Short Float %1%
Short Ratio1.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)557.4%
Min EPS beat(2)-39.67%
Max EPS beat(2)1154.47%
EPS beat(4)2
Avg EPS beat(4)282.88%
Min EPS beat(4)-39.67%
Max EPS beat(4)1154.47%
EPS beat(8)3
Avg EPS beat(8)141.82%
EPS beat(12)5
Avg EPS beat(12)87.36%
EPS beat(16)8
Avg EPS beat(16)76.39%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)-2.82%
PT rev (3m)-2.82%
EPS NQ rev (1m)966.6%
EPS NQ rev (3m)404.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)33.33%
Revenue NQ rev (3m)34.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.43 | ||
| Fwd PE | N/A | ||
| P/S | 13.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.11 | ||
| P/tB | 1.15 | ||
| EV/EBITDA | 3.56 |
EPS(TTM)0.68
EY13.47%
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.37
BVpS4.53
TBVpS4.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.33
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| ROCE | 16.62% | ||
| ROIC | 14.12% | ||
| ROICexc | 26.37% | ||
| ROICexgc | 27.79% | ||
| OM | 212.01% | ||
| PM (TTM) | 182.11% | ||
| GM | 93.01% | ||
| FCFM | N/A |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.18 | ||
| Cap/Depr | 28.09% | ||
| Cap/Sales | 7.01% | ||
| Interest Coverage | 66.45 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.69 | ||
| Altman-Z | 4.41 |
F-Score3
WACC7.18%
ROIC/WACC1.97
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.33%
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / CVAC FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 4 / 10 to CVAC.
What is the valuation status of CUREVAC NV (CVAC) stock?
ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (CVAC). This can be considered as Overvalued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (CVAC) has a profitability rating of 5 / 10.
What are the PE and PB ratios of CUREVAC NV (CVAC) stock?
The Price/Earnings (PE) ratio for CUREVAC NV (CVAC) is 7.43 and the Price/Book (PB) ratio is 1.11.
Can you provide the expected EPS growth for CVAC stock?
The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -170.56% in the next year.